BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1365055)

  • 1. [Effect of polychemotherapy in the treatment of patients with non-Hodgkin's lymphoma].
    Belić A; Popović S; Savić I
    Med Pregl; 1992; 45(5-6):188-93. PubMed ID: 1365055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
    Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
    Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of non-Hodgkin's lymphomas of medium and high malignancy].
    Mihaljević B; Petrović M; Jancić-Nedeljkov R; Jovanović V; Rolović Z
    Srp Arh Celok Lek; 1994; 122(5-6):164-8. PubMed ID: 17977418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
    Kamieńska E
    Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bulky mediastinal malignant lymphoma].
    Arai N; Nakata M; Shirai T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Jan; 31(1):26-31. PubMed ID: 8468817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The COP-BLAM III therapy of non-Hodgkin's lymphoma].
    Arai N; Hara A; Umeda M; Shirai T
    Rinsho Ketsueki; 1991 Nov; 32(11):1447-52. PubMed ID: 1721937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M; Armitage JO; Gaynor M; McDermott D; Weisenburger DD; Adler K; Beshevkin M; Silver RT; Reisman AM; Pasmantier MW
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
    Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of aggressive non-Hodgkin's lymphomas: a retrospective analysis of a single institution].
    Ohnoshi T; Hayashi K; Ueno K; Murashima M; Tada A; Mizuta J; Tagawa S; Kimura I; Motoi M
    Rinsho Ketsueki; 1989 Aug; 30(8):1201-4. PubMed ID: 2601033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.